San Francisco startup Construction Therapeutics can be engaged on an oral, after-daily GLP-one drug called GSBR-1290—the drug surpassed Wall Avenue’s anticipations in June any time a mid-phase review showed common weight loss of about six% and it programs to start Yet another mid-stage trial towards the tip of this year—that founder and CEO R